Search results
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks via Yahoo Singapore Finance· 2 months agoThis week, Bayer BAYRY released its first-quarter results. J&J JNJ announced that it will acquire a...
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
Zacks via Yahoo Singapore Finance· 3 months agoThis week AstraZeneca AZN announced a definitive agreement to acquire Fusion Therapeutics FUSN to...
Q4 2023 QuidelOrtho Corp Earnings Call
Thomson Reuters StreetEvents via Yahoo Singapore Finance· 5 months agoParticipants Douglas C. Bryant; President, CEO & Director; QuidelOrtho Corporation Joseph M. Busky; CFO; QuidelOrtho Corporation Juliet Cunningham Alexander David Nowak; Senior Research Analyst ...
AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal
Zacks via Yahoo Singapore Finance· 5 months agoData from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of...
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
Zacks via Yahoo Singapore Finance· 7 months agoAfter a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides...
AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View
Zacks via Yahoo Singapore Finance· 8 months agoAstraZeneca’s AZN third-quarter 2023 core earnings of 87 cents per American depositary share (ADS)...
Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review
Zacks via Yahoo Singapore Finance· 1 year agoFDA accepts Merck's (MRK) supplemental biologics license application for Keytruda plus chemotherapy...
AstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Singapore Finance· 1 year agoHigher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are...
Roche (RHHBY) Announces Data on Tecentriq Combo for HCC
Zacks via Yahoo Singapore Finance· 1 year agoRoche's (RHHBY) new data from the late-stage IMbrave050 study reveals that the combination of...
Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail
Zacks via Yahoo Singapore Finance· 1 year agoMerck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval...
